BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berenguer J, Alvarez-pellicer J, Carrero A, Von Wichmann MA, López-aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellón JM, González-garcía J. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. Journal of Hepatology 2013;58:1104-12. [DOI: 10.1016/j.jhep.2013.01.042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Bichoupan K, Dieterich DT. Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs 2014;74:951-61. [PMID: 24866024 DOI: 10.1007/s40265-014-0232-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Macias J, Marquez M, Tellez F, Merino D, Jimenez-aguilar P, Lopez-cortes LF, Ortega E, von Wichmann MA, Rivero A, Mancebo M, Santos J, Perez-perez M, Suarez-lozano I, Romero-palacios A, Torres-cornejo A, Pineda JA. Risk of Liver Decompensation Among HIV/Hepatitis C Virus-Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy. Clinical Infectious Diseases 2013;57:1401-8. [DOI: 10.1093/cid/cit537] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
3 Alvaro-Meca A, Berenguer J, Díaz A, Micheloud D, Aldámiz-Echevarría T, Fanciulli C, Resino S. Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. PLoS One 2017;12:e0179493. [PMID: 28617855 DOI: 10.1371/journal.pone.0179493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 Berenguer J, Zamora FX, Aldámiz-echevarría T, Von Wichmann MA, Crespo M, López-aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez-pellicer J, Esteban H, Bellón JM, González-garcía J, Miralles P, Cosín J, López J, Padilla B, Parras F, Carrero A, Aldamiz-echevarría T, Tejerina F, Gutiérrez I, Ramírez M, Carretero S, Bellón J, Berenguer J, Alvarez-pellicer J, Rodríguez E, Arribas J, Montes M, Bernardino I, Pascual J, Zamora F, Peña J, Arnalich F, Díaz M, González-garcía J, Bustinduy M, Iribarren J, Rodríguez-arrondo F, Von-wichmann M, Blanes M, Cuellar S, Lacruz J, Montero M, Salavert M, López-aldeguer J, Callau P, Miró J, Gatell J, Mallolas J, Ferrer A, Galindo M, Van den Eynde E, Pérez M, Ribera E, Crespo M, Vergas J, Téllez M, Casado J, Dronda F, Moreno A, Pérez-elías M, Sanfrutos M, Moreno S, Quereda C, Jou A, Tural C, Arranz A, Casas E, de Miguel J, Schroeder S, Sanz J, Condés E, Barros C, Sanz J, Santos I, Hernando A, Rodríguez V, Rubio R, Pulido F, Domingo P, Guardiola J, Ortiz L, Ortega E, Torres R, Cervero M, Jusdado J, Rodríguez-zapata M, Pérez G, Gaspar G, Barquilla E, Ramírez M, Moyano B, Aznar E, Esteban H; for the Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus. Clinical Infectious Diseases 2015;60:950-8. [DOI: 10.1093/cid/ciu939] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
5 Morales MK, Lambing T, Husson J. Review: Evaluation and Management of the HIV/HCV Co-Infected Kidney or Liver Transplant Candidate. Curr Treat Options Infect Dis 2020;12:87-111. [DOI: 10.1007/s40506-020-00220-x] [Reference Citation Analysis]
6 Allen J, Smith C, Bhagani S. Will antiretroviral therapy reduce HIV-related liver risk?: . Current Opinion in HIV and AIDS 2014;9:48-53. [DOI: 10.1097/coh.0000000000000022] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol 2017;206:165-74. [PMID: 28214926 DOI: 10.1007/s00430-017-0497-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
8 Casado JL, Esteban MA, Bañón S, Moreno A, Perez-Elías MJ, Mateos ML, Moreno S, Quereda C. Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response. Dig Dis Sci 2015;60:3473-81. [PMID: 26112991 DOI: 10.1007/s10620-015-3773-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
9 Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep. 2013;10:226-234. [PMID: 23832718 DOI: 10.1007/s11904-013-0169-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
10 Alvaro-Meca A, Ryan P, Martínez-Larrull E, Micheloud D, Berenguer J, Resino S. Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997-2013): A nationwide population-based study in Spain. Eur J Intern Med 2018;48:69-74. [PMID: 29102088 DOI: 10.1016/j.ejim.2017.10.012] [Reference Citation Analysis]
11 Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
12 Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63. [PMID: 29098647 DOI: 10.1007/s15010-017-1093-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Cordero-Ruiz P, Carmona-Soria I, Rodríguez-Téllez M, Caunedo-Alvarez A, Quezada-Pacheco RH, Flores-Cucho A, Romero-Gómez M, Vilches-Arenas Á. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response. Eur J Gastroenterol Hepatol 2017;29:792-9. [PMID: 28445251 DOI: 10.1097/MEG.0000000000000886] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597-605. [PMID: 23768747 DOI: 10.1016/s1473-3099(13)70149-x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 56] [Article Influence: 16.6] [Reference Citation Analysis]
15 Alvaro-Meca A, Ryan P, Micheloud D, De Miguel A, Berenguer J, Resino S. Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study. Sci Rep 2018;8:12137. [PMID: 30108235 DOI: 10.1038/s41598-018-29739-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Berenguer J, Zamora FX, Carrero A, Von Wichmann MA, Crespo M, López-aldeguer J, Aldámiz-echevarría T, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Esteban H, Bellón JM, González-garcía J. Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis. JAIDS Journal of Acquired Immune Deficiency Syndromes 2014;66:280-7. [DOI: 10.1097/qai.0000000000000156] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
17 Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C, Plaza Z, Soriano V. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat 2014;21:475-9. [PMID: 24750394 DOI: 10.1111/jvh.12180] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
18 Pérez-Latorre L, Rivero-Juárez A, Hontañón V, Díez C, Cuenca F, Martín-Carbonero ML, Montes ML, Bellón JM, Aldámiz-Echevarría T, Carrero A, Rivero A, González-García J, Berenguer J. Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C. Open Forum Infect Dis 2016;3:ofw212. [PMID: 27833930 DOI: 10.1093/ofid/ofw212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Rockstroh JK, Bhagani S. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals. BMC Med. 2013;11:234. [PMID: 24228933 DOI: 10.1186/1741-7015-11-234] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
20 Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology. 2014;60:1187-1195. [PMID: 25065814 DOI: 10.1002/hep.27340] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]